Literature DB >> 2930604

Microheterogeneity of alpha 1-acid glycoprotein in the detection of intercurrent infection in patients with rheumatoid arthritis.

T Pawlowski1, S H Mackiewicz, A Mackiewicz.   

Abstract

We evaluated the clinical usefulness of determinations of alpha 1-acid glycoprotein (AGP) microheterogeneity in distinguishing patients who have active rheumatoid arthritis (RA) from those who have RA and an intercurrent infection. AGP microheterogeneity was studied by affinity electrophoresis with concanavalin A as the ligand, and the results were expressed as reactivity coefficients (RC). Significant differences were found between the mean RC (+/- SD) in healthy individuals (1.27 +/- 0.16) and the mean RC in RA patients with intercurrent infection (1.74 +/- 0.90), as well as with the mean RC in RA patients with grades III and IV disease activity (0.92 +/- 0.18 and 0.81 +/- 0.25, respectively). Moreover, an additional microheterogeneous form of AGP, similar to that observed in non-RA patients with infections, was noted in RA patients with infections (sensitivity 100%, specificity 100%). The results show that an increase in AGP reactivity with concanavalin A is a sensitive indicator of intercurrent infection in patients with RA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930604     DOI: 10.1002/anr.1780320319

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Acute phase response in rheumatoid arthritis patients treated with low doses of cyclosporin A.

Authors:  J K Lacki; W Porawska; M Sobieska; S H Mackiewicz; W Müller
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

2.  Comparison of microheterogeneity of alpha-1-acid-glycoprotein in serum and synovial fluid from rheumatoid arthritis patients.

Authors:  J K Lacki; K Klama; W Samborski; S H Mackiewicz; W Muller
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 3.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

4.  Does methotrexate affect serum level of IgA-alpha-1 antitrypsin complex in early rheumatoid arthritis?

Authors:  J K Lacki; T Schochat; K Klama; S H Mackiewicz; W Müller
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

5.  Microheterogeneity of alpha 1-acid glycoprotein in patients with rheumatoid arthritis.

Authors:  J K Lacki; M Sobieska; P Leszczynski; K Wiktorowicz
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

6.  Microheterogeneity of alpha 1 acid glycoprotein in rheumatoid arthritis: dependent on disease duration?

Authors:  P Hrycaj; M Sobieska; S Mackiewicz; W Müller
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

7.  Alpha 1-acid glycoprotein expression in human leukocytes: possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis.

Authors:  T Nakamura; P G Board; K Matsushita; H Tanaka; T Matsuyama; T Matsuda
Journal:  Inflammation       Date:  1993-02       Impact factor: 4.092

8.  Different capabilities of monocytes from patients with systemic lupus erythematosus and rheumatoid arthritis to induce glycosylation alterations of acute phase proteins in vitro.

Authors:  A Mackiewicz; M Sobieska; M Kapciñska; S H Mackiewicz; K E Wiktorowicz; T Pawłowski
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Glycosylation of alpha 1-acid glycoprotein in septic shock: changes in degree of branching and in expression of sialyl Lewis(x) groups.

Authors:  E C Brinkman-van der Linden; E C van Ommen; W van Dijk
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

10.  Still's disease in children and adults: a distinct pattern of acute-phase proteins.

Authors:  M Sobieska; K Fassbender; A Aeschlimann; P Bourgeois; S Mackiewicz; W Müller
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.